Boehringer Ingelheim GmbH
Leoforos Andrea Syngrou 340, 176 73 Kallithea, Greece
Boehringer Ingelheim vaccinates over 100 billion birds with VAXXITEK® HVT + IBD since 2006
- VAXXITEK® HVT + IBD provides a life-long immunity against Infectious bursal disease and Marek's disease
- It is the first vector vaccine to have been launched on the avian market
- VAXXITEK® HVT + IBD is registered in more than 75 countries
Boehringer Ingelheim celebrates a milestone of over 100 billion birds vaccinated with VAXXITEK® HVT + IBD achieved in October 2018. This avian vaccine protects against two major immunosuppressive diseases.
VAXXITEK® HVT + IBD was the first vector vaccine launched on the avian vaccine market. It is a HVT-vector vaccine carrying the gene of the immunogenic protein of the IBD virus (VP2).
VAXXITEK®HVT + IBD protects against Infectious bursal disease, also called Gumboro disease, a highly contagious viral infection leading to immunosuppression, and Marek’s disease, a herpes virus infection causing tumours and lesions. VAXXITEK® HVT + IBD helps to build and strengthen a stronger immune foundation for the birds leading to better flock health and performance.
VAXXITEK® HVT + IBD was launched in 2006 in Brazil and was then commercialized in Europe, USA, Latin America, China , many countries in Asia, Middle East and Africa. To date, it is registered in more than 75 countries.
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our Annual Report.